Skip to main content
Top
Published in: Journal of Cancer Education 2/2014

01-06-2014

Physician Behaviors to Promote Informed Decisions for Prostate Cancer Screening: a National Research Network Study

Authors: Suzanne K. Linder, Michael A. Kallen, Patricia Dolan Mullen, James M. Galliher, Paul R. Swank, Evelyn C. Y. Chan, Robert J. Volk

Published in: Journal of Cancer Education | Issue 2/2014

Login to get access

Abstract

Clinical guidelines for prostate cancer screening (PCS) advise physicians to discuss the potential harms and benefits of screening. However, there is a lack of training programs for informed decision-making (IDM), and it is unknown which IDM behaviors physicians have the most difficulty performing. Identifying difficult behaviors can help tailor training programs. In the context of developing a physician-IDM program for PCS, we aimed to describe physicians’ use of nine key IDM behaviors for the PCS discussion and to examine the relation between the behaviors and physician characteristics. A cross-sectional sample of The American Academy of Family Physicians National Research Network completed surveys about their behavior regarding PCS (N = 246; response rate = 58 %). The surveys included nine physician key IDM behaviors for PCS and a single-item question describing their general practice style for PCS. The most common IDM behavior was to invite men to ask questions. The two least common reported behaviors concerned patients uncertain about screening (i.e., arrange follow-up and provide additional information for undecided men). Physicians reported difficulty with these two behaviors regardless whether they reported to discuss or not to discuss PCS with patients. Reported use of key IDM behaviors was associated with a general practice style for PCS and being affiliated with a residency-training program. Physician training programs for IDM should include physician skills to address the needs of patients uncertain about screening. Future research should determine if actual behavior is associated with self-reported behavior for the PCS discussion.
Literature
8.
go back to reference Dunn AS, Shridharani KV, Lou W, Bernstein J, Horowitz CR (2001) Physician-patient discussions of controversial cancer screening tests. Am J Prev Med 20(2):130–134CrossRefPubMed Dunn AS, Shridharani KV, Lou W, Bernstein J, Horowitz CR (2001) Physician-patient discussions of controversial cancer screening tests. Am J Prev Med 20(2):130–134CrossRefPubMed
13.
go back to reference Briss P, Rimer B, Reilley B et al (2004) Promoting informed decisions about cancer screening in communities and healthcare systems. Am J Prev Med 26(1):67–80CrossRefPubMed Briss P, Rimer B, Reilley B et al (2004) Promoting informed decisions about cancer screening in communities and healthcare systems. Am J Prev Med 26(1):67–80CrossRefPubMed
14.
go back to reference Sheridan SL, Harris RP, Woolf SH (2004) Shared decision making about screening and chemoprevention: a suggested approach from the U.S. Preventive Services Task Force. Am J Prev Med 26(1):56–66CrossRefPubMed Sheridan SL, Harris RP, Woolf SH (2004) Shared decision making about screening and chemoprevention: a suggested approach from the U.S. Preventive Services Task Force. Am J Prev Med 26(1):56–66CrossRefPubMed
15.
go back to reference Gattellari M, Donnelly N, Taylor N, Meerkin M, Hirst G, Ward JE (2005) Does ‘peer coaching’ increase GP capacity to promote informed decision making about PSA screening? A cluster randomised trial. Fam Pract 22(3):253–265. doi:10.1093/fampra/cmi028 CrossRefPubMed Gattellari M, Donnelly N, Taylor N, Meerkin M, Hirst G, Ward JE (2005) Does ‘peer coaching’ increase GP capacity to promote informed decision making about PSA screening? A cluster randomised trial. Fam Pract 22(3):253–265. doi:10.​1093/​fampra/​cmi028 CrossRefPubMed
16.
go back to reference Agency for Healthcare Research and Quality. Five major steps to intervention (The “5A’s”). Secondary Five major steps to intervention (The “5A’s”). http://www.ahrq.gov/clinic/tobacco/5steps.htm Agency for Healthcare Research and Quality. Five major steps to intervention (The “5A’s”). Secondary Five major steps to intervention (The “5A’s”). http://​www.​ahrq.​gov/​clinic/​tobacco/​5steps.​htm
18.
go back to reference Linder SK, Hawley ST, Cooper CP, Scholl LE, Jibaja-Weiss M, Volk RJ. Primary care physicians’ reported use of pre-screening discussions for prostate cancer screening: a cross-sectional survey. BMC Fam Pract 2009;10:19 doi: 10.1186/1471-2296-10-19[published Online First: Epub Date]|. Linder SK, Hawley ST, Cooper CP, Scholl LE, Jibaja-Weiss M, Volk RJ. Primary care physicians’ reported use of pre-screening discussions for prostate cancer screening: a cross-sectional survey. BMC Fam Pract 2009;10:19 doi: 10.​1186/​1471-2296-10-19[published Online First: Epub Date]|.
19.
go back to reference Volk RJ, Spann SJ, Cass AR, Hawley ST (2003) Patient education for informed decision making about prostate cancer screening: a randomized controlled trial with 1-year follow-up. Ann Fam Med 1(1):22–28PubMedCentralCrossRefPubMed Volk RJ, Spann SJ, Cass AR, Hawley ST (2003) Patient education for informed decision making about prostate cancer screening: a randomized controlled trial with 1-year follow-up. Ann Fam Med 1(1):22–28PubMedCentralCrossRefPubMed
Metadata
Title
Physician Behaviors to Promote Informed Decisions for Prostate Cancer Screening: a National Research Network Study
Authors
Suzanne K. Linder
Michael A. Kallen
Patricia Dolan Mullen
James M. Galliher
Paul R. Swank
Evelyn C. Y. Chan
Robert J. Volk
Publication date
01-06-2014
Publisher
Springer US
Published in
Journal of Cancer Education / Issue 2/2014
Print ISSN: 0885-8195
Electronic ISSN: 1543-0154
DOI
https://doi.org/10.1007/s13187-014-0613-2

Other articles of this Issue 2/2014

Journal of Cancer Education 2/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine